Should I Buy BTAI? BTAI 2026 Analysis

Should You Buy BioXcel Therapeutics Inc (BTAI) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

1.620

1 Day change

-3.57%

52 Week Range

8.080

Analysis Updated At

2026/01/28

Not a good buy right now for a Beginner, long-term investor with $50k–$100k. The stock is in a clear downtrend, there are no supportive proprietary buy signals, no recent positive news catalysts, and the latest quarter shows sharp revenue decline with continued large losses. This setup favors capital preservation over initiating a long-term position today.

Technical Analysis

Trend is bearish. Price is 1.7011 (-3.96% regular session) and sits below key moving averages with a bearish stack (SMA_200 > SMA_20 > SMA_5), signaling sustained downside momentum. MACD histogram is negative (-0.0129) and expanding lower, confirming weakening momentum. RSI_6 is ~30.12 (near oversold), which can allow short bounces, but it is not a durable long-term buy signal while the trend remains down. Key levels: immediate support S1 ~1.731 (already below/around it) and S2 ~1.643; resistance/pivot overhead at ~1.875, then ~2.018 and ~2.106. Pattern-based projection provided is mildly negative over a month (-4.16%), reinforcing the bearish bias.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Options look effectively illiquid/inconclusive from the provided fields (most values missing) and the put-call ratios at 0.0 suggest no meaningful put activity captured rather than a strong bullish signal. Historical volatility is extremely high (~103.96), which aligns with a speculative, unstable tape rather than steady long-term accumulation.

Technical Summary

Sell

Buy

Positive Catalysts

can support a short-term technical bounce if price holds the 1.64–1.73 support zone and reclaims the 1.875 pivot. Hedge fund and insider activity are neutral (no recent significant selling pressure indicated by the provided trend summary).

Neutral/Negative Catalysts

No news in the last week (no near-term event-driven catalyst identified). Strongly bearish technical structure (bearish moving-average stack + negative/expanding MACD). The stock is trading below the pivot with nearby supports at risk (1.731 and 1.643). High realized volatility indicates a speculative profile. The provided pattern-based outlook is negative over the next month (-4.16%).

Financial Performance

Latest reported quarter: 2025/Q3. Revenue fell to $98,000, down -54.21% YoY, indicating significant contraction. Net income improved YoY to -$30.911M (still a large loss). EPS was -2.18 (reported as down -57.67% YoY), suggesting per-share performance worsened year-over-year despite the net-loss improvement line item. Gross margin is listed as 88.78 with a large YoY decline (-119.87%), pointing to unstable/volatile operating metrics. Overall, the quarter does not show the kind of consistent growth trend a beginner long-term investor typically wants.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating trend or price target change data was provided, so a Wall Street consensus pros/cons view cannot be reliably summarized from this dataset. (Trading trends provided: Hedge Funds Neutral; Insiders Neutral. No recent congress trading data; no noted politician/influential-figure transactions in the provided data.)

2 Analyst Rating

Wall Street analysts forecast BTAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BTAI is 5.5 USD with a low forecast of 1 USD and a high forecast of 10 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

1 Sell

Hold

Current: 1.680

Low

Averages

5.5

High

Current: 1.680

Low

Averages

5.5

High

Mizuho

Neutral

maintain

$2 -> $4

AI Analysis

2025-09-12

Reason

Mizuho

Price Target

$2 -> $4

AI Analysis

2025-09-12

maintain

Neutral

Reason

Mizuho raised the firm's price target on BioXcel Therapeutics to $4 from $2 and keeps a Neutral rating on the shares. The firm cites the positive Phase 3 SERENITY At-Home study data for BXCL501 for the target doubling. Mizuho's risk-adjusted sales estimate for Igalmi in peak year 2037 is now projected at $390M across three indications, from $325M prior. However, the firm sees continued uncertainty around what type of financing BioXcel will undertake to provide more financial stability.

H.C. Wainwright

Raghuram Selvaraju

Buy

maintain

$8 -> $10

2025-08-15

Reason

H.C. Wainwright

Raghuram Selvaraju

Price Target

$8 -> $10

2025-08-15

maintain

Buy

Reason

H.C. Wainwright analyst Raghuram Selvaraju raised the firm's price target on BioXcel Therapeutics to $10 from $8 and keeps a Buy rating on the shares following the Q2 report. The firm cites "heightened enthusiasm" for BXCL501's prospects for the target increase. The analyst views the SERENITY readout as low-risk and believes BioXcel could file for the expanded label of BXCL501 by the end of this year and may receive the label extension in the back half of 2026.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BTAI

Unlock Now

BTAI Should I Buy

BTAI Should I Buy

Should You Buy BioXcel Therapeutics Inc (BTAI) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch